Japanese researchers on Friday said they had transplanted stem cells from the name "iPS" into the brain of a patient with Parkinson's disease, the first such trial in the world.
The Kyoto University team sprayed 2.4 million of these multifunctional cells, can give any type of cell, in the left part of brain, during the operation of three hours last month.
The man, in his half, was well tolerated and will now be under supervision for two years, says Kyoto University in a statement.
If a problem does not appear in the next six months, researchers will implant 2.4 million more cells, this time is the right part of the patient's brain.
These iPS cells of healthy donors are believed to develop to become dopamine neurons, a motor-transmitter that is about motor control.
Kyoto University announced in July that this was being carried out clinical trial with seven participants aged 50 to 69.
"I am patient and patient for their courageous and decisive participation"said Professor Jun Takahashi, quoted on Friday by the NHK public television channel.
y Parkinson's Disease has been marked by the decline o these neurons resulting in gradual exacerbation of the symptoms such as roaming, limitation strength, and reducing body movement.
It affects more than 10 million people worldwide, according to the United States Parkinson's Disease Foundation. Therapies currently available "improve symptoms without slowing down the sequence of the disease"said this base.
The aim of this new research is to reduce the damage.
This test follows an experiment that is carried out on monkeys with human origin cell cells that have been possible to improve the capacity of Parkinson's habitats to make movements, according to a study published at the end of August 2017 in the Natural Science journal. The survival of graffiti cells, through injection to the brain of primates, was observed for two years without a tumor appearance.
y Multi-drug stem cells have triggered (iPS for multi-drug cell cells triggered) are adult cells that are brought back to the near-embryonic state by repeating them and expressing four genera (usually inactive in adult cells). this genetic treatment give them the ability to produce any type of cells (pluripotency), depending on where they are transplanted into the body.
The use of iPS cells does not cause basic ethical problems, unlike cell cells taken by human embryos.